(A) Selected advances in role of stem cell transplantation in hemophagocytic lymphohistiocytosis and primary immunodeficiencies. (B) Schema of BMT CTN study 1204 transplant regimen and timing of alemtuzumab dosing (vs prior studies). Mel, melphalan; OS, overall survival; RIC, reduced-intensity conditioning; TRM, transplant-related mortality.